Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study.

摘要: Objective : To evaluate the effects of flumazenil on hepatic encephalopathy in patients with cirrhosis. Design Double-blind randomized study. Setting Liver intensive care unit over a 2-year period. Patients Fourteen cirrhosis (median age 54 years, range 41-73 years), comprising 10 men and four women enrolled during 18 episodes encephalopathy. Methods Placebo or (1 mg at 0.1 mg/min infusion rate) was infused coded vials. The patients' graded clinically by electroencephalography (EEG). Results In eight placebo first no improvement occurred (0%). During 12 encephalopathy, administered EEG recording improved within 7 min (range 4-47 ; out cases 66 versus 0% for placebo, respectively P<0.01) modest clinical observed 83 30-340 min). amount averaged 0.7 0.4-1 mg). Conclusions results but rapid grading to moderate delayed grade